Additional file 8: Study characteristics associated with citation by systematic reviews

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Covariates (number of trials)** | **Number (%) of published trials** | **Probability/ Odds ratio** | **95% CI** | **p-value** |
| Intercept (probability) |  | 0.498 | 0.382-0.615 | NA |
| IIT Public International (200) | 125 (63) | 1.357 | 0.838-2.196 | 0.2133 |
| IST Commercial Germany (171) | 89 (52) | 0.824 | 0.505-1.341 | 0.4360 |
| IST Commercial International (200) | 75 (38) | 0.407 | 0.252-0.652 | 0.0002 |
| Non-drug trials (356) versus drug trials (335)  | 172 (48) versus 188 (56)  | 0.824 | 0.598-1.135 | 0.2362 |
| Study size: n >150 (344) versus n ≤ 150 (346)  | 208 (60) versus 152 (44)  | 2.195 | 1.588-3.048 | 0.0000 |
| Number of primary outcome(s): > 1 (165) versus 1 (525) | 86 (52) versus 273 (52)  | 1.105 | 0.763-1.602 | 0.5979 |

Impact of the covariates on the probability of a study to be published. The second column contains in the first row the probability of being published for the intercept category and in the other rows the odds ratios for the other covariate categories.